KURA ONCOLOGY INC (KURA) Stock Price & Overview
NASDAQ:KURA • US50127T1097
Current stock price
The current stock price of KURA is 8.61 USD. Today KURA is up by 3.24%. In the past month the price increased by 1.18%. In the past year, price increased by 46.18%.
KURA Key Statistics
- Market Cap
- 760.521M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.18
- Dividend Yield
- N/A
KURA Stock Performance
KURA Stock Chart
KURA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to KURA. When comparing the yearly performance of all stocks, KURA turns out to be only a medium performer in the overall market: it outperformed 67.1% of all stocks.
KURA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KURA. While KURA seems to be doing ok healthwise, there are quite some concerns on its profitability.
KURA Earnings
On March 5, 2026 KURA reported an EPS of -0.92 and a revenue of 17.34M. The company missed EPS expectations (-86.01% surprise) and missed revenue expectations (-77.38% surprise).
KURA Forecast & Estimates
21 analysts have analysed KURA and the average price target is 33.1 USD. This implies a price increase of 284.48% is expected in the next year compared to the current price of 8.61.
For the next year, analysts expect an EPS growth of -1.15% and a revenue growth -9.18% for KURA
KURA Groups
Sector & Classification
KURA Financial Highlights
Over the last trailing twelve months KURA reported a non-GAAP Earnings per Share(EPS) of -3.18. The EPS decreased by -56.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.74% | ||
| ROE | -160.03% | ||
| Debt/Equity | 0.06 |
KURA Ownership
KURA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KURA
Company Profile
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 260 full-time employees. The company went IPO on 2015-11-05. The firm is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.
Company Info
IPO: 2015-11-05
KURA ONCOLOGY INC
4930 Directors Place, Suite 500
San Diego CALIFORNIA 92130 US
CEO: Troy E. Wilson
Employees: 260
Phone: 13026587581
KURA ONCOLOGY INC / KURA FAQ
What does KURA ONCOLOGY INC do?
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 260 full-time employees. The company went IPO on 2015-11-05. The firm is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.
What is the stock price of KURA ONCOLOGY INC today?
The current stock price of KURA is 8.61 USD. The price increased by 3.24% in the last trading session.
Does KURA stock pay dividends?
KURA does not pay a dividend.
How is the ChartMill rating for KURA ONCOLOGY INC?
KURA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for KURA ONCOLOGY INC?
KURA ONCOLOGY INC (KURA) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of KURA ONCOLOGY INC (KURA)?
KURA ONCOLOGY INC (KURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.18).
What is the employee count for KURA stock?
KURA ONCOLOGY INC (KURA) currently has 260 employees.